Loading...
Market
In how many countries will Kisunla™ be approved by end of 2025?
2
Resolution / Starting Odds
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
Eli Lilly's official announcements and international regulatory agency reports
Story
Eli Lilly's Second 'Game-Changing' Alzheimer's Drug Kisunla™ Approved in UK
Oct 23, 2024, 09:30 AM
Eli Lilly's Alzheimer's treatment, Kisunla™ (donanemab-azbt), has received marketing authorization in Great Britain. The approval by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) allows the drug to be used for treating mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients who are Apolipoprotein E Ε4 heterozygotes or non-carriers. This marks a significant development in Alzheimer's treatment options available in the UK. The drug, which trades under the ticker $LLY, is considered the second 'game-changing' Alzheimer's drug to receive approval in the UK.
View original story
Similar markets
Less than 20 • 33%
20-40 • 33%
More than 40 • 33%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
More than 20 countries • 33%
10 to 20 countries • 34%
Less than 10 countries • 33%
0-10 • 25%
11-20 • 25%
21-30 • 25%
31+ • 25%
Yes • 50%
No • 50%
1-3 countries • 25%
4-6 countries • 25%
7-9 countries • 25%
10 or more countries • 25%
Below 10% • 33%
10-20% • 33%
Above 20% • 33%
Less than 5 countries • 25%
5 to 10 countries • 25%
11 to 20 countries • 25%
More than 20 countries • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%
Less than $100 million • 25%
$100 million - $299 million • 25%
$300 million - $499 million • 25%
$500 million or more • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61+ • 25%